Delusions associated with elevated muscarinic binding in dementia with Lewy bodies

The relation between disturbances of cholinergic neurotransmission and delusions (DELs) has not been investigated in degenerative dementias such as dementia with Lewy bodies (DLB). A cohort of dementia patients were assessed with standardized clinical evaluations (including the Columbia University Scale for Psychopathology in Alzheimer's Disease), which were repeated annually until death. DLB was confirmed neuropathologically in 21 patients. Neurochemical evaluation included M1 receptor autoradiography (pirenzepine binding), biochemical measurement of choline acetyltransferase (ChAT), and acetylcholinesterase (AChE) histochemistry in brain regions hypothesized to be involved in the genesis of psychosis. Compared with 11 age‐matched controls, ChAT and pirenzepine levels were most extensively reduced in the temporal and parietal neocortex of DLB patients. In Brodmann area 36, DELs were significantly associated with elevated pirenzepine binding (131.0 vs 93.5, t = 2.7), whereas visual hallucinations were associated with significant reductions in ChAT (1.7 vs 2.5, t = 2.5). There were no significant associations with other areas or with cholinesterase. Although DELs and visual hallucinations were both linked with disturbances in cholinergic neurotransmission, the nature of the associations was different. Upregulation of the postsynaptic muscarinic receptor may be central in the genesis of DELs, with important treatment implications. Ann Neurol 2000;48:868–876

[1]  I. McKeith,et al.  Neuroleptic sensitivity to risperidone in Lewy body dementia , 1995, The Lancet.

[2]  Hans Förstl,et al.  Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings , 1993, Acta psychiatrica Scandinavica.

[3]  I. McKeith,et al.  Simple Standardised NeuropsychologicalAssessments Aid in the Differential Diagnosis of Dementia with Lewy Bodies from Alzheimer’s Disease and Vascular Dementia , 1999, Dementia and Geriatric Cognitive Disorders.

[4]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[5]  K Ugurbil,et al.  Activation of visuomotor systems during visually guided movements: a functional MRI study. , 1998, Journal of magnetic resonance.

[6]  D. Bennett,et al.  Hallucinations and associated factors in Alzheimer's disease. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[7]  P. Ince,et al.  The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies , 1997, Acta neurologica Scandinavica.

[8]  J. Pearce Longus cervicis colli "myositis" (syn: retropharyngeal tendinitis) , 1996, Journal of neurology, neurosurgery, and psychiatry.

[9]  Mary Johnson,et al.  Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus , 1993, Hippocampus.

[10]  Wayne C. Drevets,et al.  Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type , 1989, Biological Psychiatry.

[11]  C. Ballard,et al.  Paranoid features in the elderly with dementia , 1991 .

[12]  G. Stebbins,et al.  Intravenous levodopa in hallucinating Parkinson's disease patients , 1998, Neurology.

[13]  Mrinalini Honavar,et al.  Lewy bodies and response to tacrine in Alzheimer's disease , 1994, The Lancet.

[14]  P V Rabins,et al.  The impact of dementia on the family. , 1982, JAMA.

[15]  L. Schneider,et al.  Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. , 1994, Archives of neurology.

[16]  Organic delusions: phenomenology, anatomical correlations, and review. , 1985, The British journal of psychiatry : the journal of mental science.

[17]  A. Kurz,et al.  DELUSIONS AND HALLUCINATIONS IN ALZHEIMER'S DISEASE: RESULTS FROM A TWO‐YEAR LONGITUDINAL STUDY , 1996 .

[18]  J. R. Baker,et al.  The hippocampal formation participates in novel picture encoding: evidence from functional magnetic resonance imaging. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Jeste,et al.  Cognitive deficits of patients with Alzheimer's disease with and without delusions. , 1992, The American journal of psychiatry.

[20]  Robert H. Perry,et al.  Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly , 1990, Journal of the Neurological Sciences.

[21]  E. Perry,et al.  Convergent cholinergic activities in aging and Alzheimer's disease , 1992, Neurobiology of Aging.

[22]  J. Moossy,et al.  Neuropathologic and neurochemical correlates of psychosis in primary dementia. , 1991, Archives of neurology.

[23]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[24]  D. Wong,et al.  Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). , 1994, The Journal of pharmacology and experimental therapeutics.

[25]  K. Marder,et al.  The Columbia University Scale for Psychopathology in Alzheimer's disease. , 1992, Archives of neurology.

[26]  M. Olianas,et al.  Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor , 1997, British journal of pharmacology.

[27]  E. Perry,et al.  Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. , 1999, The American journal of psychiatry.

[28]  B. Gulanski,et al.  Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease , 1998, Neurology.

[29]  G. Wilcock,et al.  The prevalence and phenomenology of psychotic symptoms in dementia sufferers , 1995 .

[30]  J. Copeland,et al.  Computerized diagnosis from a standardized history schedule: A preliminary communication about the organic section of the HAS–AGECAT system , 1992 .

[31]  P. Hedera,et al.  Delirium in Alzheimer Disease , 1997, Alzheimer disease and associated disorders.

[32]  E. Richelson,et al.  Muscarinic m4 receptor activation by some atypical antipsychotic drugs. , 1997, European journal of pharmacology.

[33]  H. Haeske-Dewick Hallucinations in Parkinson's disease: Characteristics and associated clinical features , 1995 .

[34]  Abraham Weizman,et al.  Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. , 1996, Advances in neurology.

[35]  C. Tanner,et al.  Early dopaminergic drug-induced hallucinations in parkinsonian patients , 1998, Neurology.

[36]  J. Grace,et al.  Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease , 1998, The Lancet.

[37]  M. Hutchinson,et al.  Cholinesterase inhibition in Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[38]  D. Bass,et al.  Symptoms of mental impairment among elderly adults and their effects on family caregivers. , 1986, Journal of gerontology.

[39]  A. Burns,et al.  Psychiatric Phenomena in Alzheimer's Disease. I: Disorders of Thought Content , 1990, British Journal of Psychiatry.

[40]  K. Rockwood,et al.  Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients , 1998, International Psychogeriatrics.

[41]  F. Huppert,et al.  CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia , 1986, British Journal of Psychiatry.

[42]  E. Perry,et al.  Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia , 1990, Journal of neurochemistry.

[43]  G. Zubenko,et al.  Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease , 1991, Biological Psychiatry.

[44]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[45]  D. Jeste Mechanisms of Drug Action on the Nervous System, 2nd ed , 1992 .

[46]  S. Zorn,et al.  Clozapine is a potent and selective muscarinic M4 receptor agonist. , 1994, European journal of pharmacology.

[47]  R. Levy,et al.  Neuropathological Correlates of Psychotic Phenomena in Confirmed Alzheimer's Disease , 1994, British Journal of Psychiatry.

[48]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.